What is HC Wainwright’s Forecast for CNTX Q3 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.05) EPS.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.

A number of other brokerages have also commented on CNTX. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. JMP Securities initiated coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Stock Up 13.2 %

Shares of NASDAQ:CNTX opened at $0.87 on Monday. The firm has a market cap of $64.87 million, a P/E ratio of -0.95 and a beta of 2.06. Context Therapeutics has a 12 month low of $0.64 and a 12 month high of $2.75. The company’s 50-day moving average price is $0.84 and its two-hundred day moving average price is $1.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. MPM Bioimpact LLC bought a new position in shares of Context Therapeutics during the fourth quarter worth $15,441,000. Blue Owl Capital Holdings LP raised its stake in Context Therapeutics by 17.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock worth $6,676,000 after buying an additional 946,638 shares during the period. Franklin Resources Inc. lifted its holdings in Context Therapeutics by 115.9% during the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock worth $4,204,000 after acquiring an additional 2,149,392 shares in the last quarter. Allostery Investments LP acquired a new position in Context Therapeutics in the fourth quarter valued at about $998,000. Finally, Geode Capital Management LLC increased its holdings in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock worth $661,000 after acquiring an additional 52,830 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.